MYL News and Press, Mylan N.V. From 05/10/20

A dividend cut is on the way for one of the biggest drugmakers in the world. But it's not because of the COVID-19 pandemic. It's not because of financial problems at all. Pfizer (NYSE: PFE) will lower its dividend payout at some point later this year for a straightforward reason. The pharma...

Generic drugs are crucial to our healthcare system, as they keep the costs of branded drugs down once their patents expire. Although there are many manufacturers of generic drugs globally, competition in this $340 billion global market can be quite intense. Fortunately, there is one company in t...

HERTFORDSHIRE, England and PITTSBURGH , May 8, 2020 /PRNewswire/ -- Global pharmaceutical company Mylan N.V. (NASDAQ: MYL) today announced that President Rajiv Malik and Chief Financial Officer Ken Parks will present at the BofA Securities Virtual Health Care Conference 2020 ...

New York City, NY: May 06, 2020 – Published via (Wired Release):- “Market.us presents a new report titled Carboplatin Crystal Market: 2020 Research and New Innovations in Oil and Gas Sector. The prime objective of the report is to offer updates and information related to future ...

HERTFORDSHIRE, England and PITTSBURGH , May 4, 2020 /PRNewswire/ -- Mylan N.V.  (NASDAQ: MYL) has been working since its founding in 1961 to create access to medicine for patients, and that aspiration has included a strong commitment to long-term thinking, sustainability and makin...

NEW YORK, NY / ACCESSWIRE / May 1, 2020 / Halper Sadeh LLP, a global investor rights law firm, continues to investigate whether the following proposed mergers are fair to shareholders. Halper Sadeh LLP may seek increased consideration, additional disclosures and information concerning the pr...

Introduction Agile Therapeutics (NASDAQ: AGRX ) is a women’s healthcare company focused on patch-based contraceptive options. Their lead product, Twirla, is a once-a-week contraceptive patch containing a combined dose of levonorgestrel and ethinyl estradiol. Twirla was recently appr...

For years, we've seen the failure of clinical trials targeting Alzheimer's disease based on a controversial hypothesis.  Biogen 's (NASDAQ: BIIB) aducanumab may become the newest addition to the list. Should shareholders be worried about a material decline in the stock price if the U.S. F...

I love hearing feedback from readers about things that they believe will improve the value of my articles and help others better understand what is happening within the portfolios that I write about. I believe feedback is extremely important because I am a self-taught investor and that tells m...

Eagle Pharmaceuticals (NASDAQ: EGRX ) and licensee Teva Pharmaceutical Industries (NYSE: TEVA ) announce a favorable outcome in a patent dispute from would-be generic competitors to blood cancer med Bendeka (bendamustine HCl) injection. More news on: Eagle Pharmaceuticals, Inc., Teva Pha...